ReviewsProdrugs of nucleoside analogues for improved oral absorption and tissue targeting
Section snippets
INTRODUCTION
Nucleosides are building blocks of RNA and DNA. Nucleoside analogues are synthetic compounds that are structurally similar to natural nucleosides. Many nucleoside analogues have antiviral and antitumor properties. Over the last two decades, numerous nucleoside analogues and their prodrugs were developed for the treatment of patients with infections of human immunodeficiency virus (HIV), including zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir,
RATIONALE FOR PRODRUG DESIGN
For orally administered drugs, the intestinal epithelial membrane forms the first barrier to drug absorption. Therefore, for a drug to be well absorbed in the gastrointestinal tract, it needs to possess optimum physicochemical properties in order to cross the epithelial membrane by passive diffusion. Prodrug strategies are typically employed to alter lipophilicity, permeability, stability, and tissue specificity of the active drugs and thus improve drug delivery properties over the parent drug.
SCREENING PARADIGMS FOR PRODRUGS
The effectiveness of a prodrug is typically evaluated by characterization of physicochemical properties, assessment of Caco‐2 cell permeabilities and determination of pharmacokinetics (PK) and exposures in animals. Considering the data from these screening studies and additional factors, such as, ease of synthesis, cost, and toxicity of the promoiety, lead prodrugs are selected for further evaluation. Figure 2 shows the screening paradigm used in our lab for prodrugs intended to improve oral
Prodrugs of Acyclic Nucleoside Analogues
Acyclovir, ganciclovir, penciclovir, and H2G are acyclic guanosine nucleoside analogues and have potent antiviral activities (Fig. 3). They are selectively phosphorylated to the monophosphate level by a virus specified thymidine kinase and subsequently converted to di‐ and triphosphates by cellular kinases.72., 73., 74. After phosphorylation, the triphosphates either incorporate into the viral DNA resulting in chain termination or slow the elongation of viral DNA and therefore, inhibit the
CONCLUSION
Drug development efforts have been made to continually identify new therapeutic agents and prodrugs with desired drug‐like characteristics, improved therapeutic efficacy and less adverse effects. For orally administered drugs, the intestinal epithelial membrane forms the first barrier to drug absorption. Most oral drugs are absorbed into systemic circulation by passive diffusion across the intestinal epithelial membrane. Since nucleoside analogues are polar molecules and have limited membrane
REFERENCES (187)
Antiviral drugs in current clinical use
J Clin Virol
(2004)- et al.
Capecitabine: A review
Clin Ther
(2005) - et al.
Involvement of multiple transporters in the oral absorption of nucleoside analogues
Adv Drug Deliv Rev
(1999) - et al.
Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics
Annu Rep Med Chem
(2004) - et al.
Nucleoside transport in normal and neoplastic cells
Adv Enzyme Regul
(1993) - et al.
Nucleoside transporters: Molecular biology and implications for therapeutic development
Mol Med Today
(1999) - et al.
Structural modifications at the 2′‐ and 3′‐positions of some pyrimidine nucleosides as determinants of their interaction with the mouse erythrocyte nucleoside transporter
Biochem Pharmacol
(1984) Improved passive oral drug delivery via prodrugs
Adv Drug Deliv Rev
(1996)- et al.
Enzymes involved in the bioconversion of ester‐based prodrugs
J Pharm Sci
(2006) - et al.
Prodrug strategies based on intramolecular cyclization reactions
J Pharm Sci
(1997)
The design and synthesis of a new tumor‐selective fluoropyrimidine carbamate, capecitabine
Bioorg Med Chem
Prodrugs of phosphates, phosphonates, and phosphinates
Adv Drug Deliv Rev
Membrane transporter/receptor‐targeted prodrug design: Strategies for human and veterinary drug development
Adv Drug Deliv Rev
Membrane transporters
Eur J Pharm Sci
Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption
Eur J Pharm Sci
Human intestinal H+/peptide cotransporter
J Biol Chem
Molecular cloning of PEPT 2, a new membrane of the H+/peptide cotransporter family, from human kidney
Biochim Biophys Acta
Molecular cloning and tissue distribution of rat peptide transporter PE PT2
Biochim Biophys Acta
Passive and carrier‐mediated intestinal absorption components of captopril
J Pharm Sci
Transport of Valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PE PT2
J Pharm Sci
Application of high‐performance liquid chromatography to the purification of the putative intestinal peptide transporter
J Chromatogr
Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco‐2
Biochim Biophys Acta
Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE‐inhibitors: Enalapril, enalaprilat, and lisinopril
Biochim Biophys Acta
Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco‐2 cell line
J Control Release
Transport of levovirin prodrugs in the human intestinal Caco‐2 cell line
J Pharm Sci
Synthesis of analogs of L‐valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco‐2 cells
Eur J Pharm Sci
Identification of a human valacyclovirase
Pharm Res
Carrier‐mediated transport and efflux mechanisms in Caco‐2 cells
Adv Drug Deliv Rev
Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco‐2) cells
Biochim Biophys Res Commun
Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase
J Biol Chem
Desciclovir permeation of the human erythrocyte membrane by nonfacilitated diffusion
Biochem Pharmacol
Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy
Antivir Res
Direct evidence for peptide transporter (PepT1)‐mediated uptake of a nonpeptide prodrug, valacyclovir
Biochem Biophys Res Comm
Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PE PT2
Biochem Biophys Res Comm
Synthesis and characterization of novel dipeptide ester prodrugs of acyclovir
Spectrochim Acta A Mol Biomol Spectrosc
Acyclovir prodrug for the intestinal di/tri‐peptide transporter PEP T1: Comparison of in vivo bioavailability in rats and transport I Caco‐2 cells
Eur J Pharm Sci
Prodrugs of purine and pyimidine analogues for the intestinal di/tri‐peptide transporter Pep T1: Affinity for hPepT1 in Caco‐2 cells, drug release in aqueous media and in vitro metabolism
J Control Release
Antiviral prodrugs—The development of successful prodrug strategies for antiviral chemotherapy
Br J Pharmacol
Recent advances in antiviral nucleoside and nucleotide therapeutics
Curr Top Med Chem
Gemcitabine, a review of its pharmacology and clinical potential in non‐small cell lung cancer and pancreatic cancer
Drugs
Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist
Curr Drug Metab
Lessons learned from marketed and investigational prodrugs
J Med Chem
Targeted prodrug design to optimize drug delivery
AAPS Pharmsci
Current progress on esterases: From molecular structure to function
Drug Metab Dispos
Interaction of nucleoside analogues with the sodium‐nucleoside transport system in brush border membrane vesicles from human kidney
Pharm Res
Pro‐nucleotides—Recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates
Synlett
Clinical potential of the acyclic nucleoside phosphonates cidoforvir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections
Clin Microbiol Rev
Novel Phosphonate nucleosides as antiviral agents
Drugs Future
Carrier‐mediated intestinal transport of drugs
Pharm Res
Intestinal peptide transport systems and oral drug availability
Pharm Res
Cited by (145)
Prodrugs: Harnessing chemical modifications for improved therapeutics
2023, Journal of Drug Delivery Science and TechnologyUnderstanding Cu(ii)-based systems for C(sp<sup>3</sup>)-H bond functionalization: insights into the synthesis of aza-heterocycles
2022, Organic and Biomolecular ChemistrySmart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport
2022, Journal of Controlled ReleaseCitation Excerpt :In recent years there has been significant focus on intelligent prodrug design as a strategy to improve the physicochemical characteristics of difficult-to-deliver drugs. Emphasis is placed on manipulating lipophilicity, stability, permeability and facilitating tissue selectivity of the parent drug [117] when employing prodrug strategies. As an alternative for alleviating unfavourable drug characteristics, prodrug technologies can offer a variety of benefits, including i) reduced toxicity, ii) significant optimisation of physicochemical features (mainly with respect to chemical stability, intestinal permeability and aqueous solubility), iii) sustained release of the active metabolite [118] and iv) improved site-specificity and targeting [119–121].
Nanomedicine based approaches for combating viral infections
2021, Journal of Controlled ReleaseRecent advances in prodrug-based nanoparticle therapeutics
2021, European Journal of Pharmaceutics and Biopharmaceutics